Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum

by NASDAQ Market News September 12, 2019

NASDAQ Market News
Click here to email author

Adverum Biotechnologies Reports Positive 24-Week Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD

Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy

Ads